Scalper1 News
Biotech Medicines Co. (MDCO) said Wednesday that it had acquired antibiotics developer Rempex Pharmaceuticals, and Medicines Co. stock was up more than 4% in morning trading on the stock market today. Rempex has one product on the market, Minocin IV for Acinetobacter infections, which Medicines Co. will take over marketing. The company plans to file for approval of a new, improved Minocin next year, and the press release also highlighted the Scalper1 News
Scalper1 News